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Abstract
Background: The defining feature of the cerebrospinal fluid (CSF) collected from infants and children with
tuberculous meningitis (TBM), derived from an earlier untargeted nuclear magnetic resonance (NMR) metabolomics
study, was highly elevated lactic acid. Undetermined was the contribution from host response (L-lactic acid) or of
microbial origin (D-lactic acid), which was set out to be determined in this study.
Methods: In this follow-up study, we used targeted ultra-performance liquid chromatography–electrospray
ionization–tandem mass spectrometry (UPLC–ESI–MS/MS) to determine the ratio of the L and D enantiomers of
lactic acid in these CSF samples.
Results: Here we report for the first time that the lactic acid observed in the CSF of confirmed TBM cases was in
the L-form and solely a response from the host to the infection, with no contribution from any bacteria. The
significance of elevated lactic acid in TBM appears to be that it is a crucial energy substrate, used preferentially over
glucose by microglia, and exhibits neuroprotective capabilities.
Conclusion: These results provide experimental evidence to support our conceptual astrocyte–microglia lactate
shuttle model formulated from our previous NMR-based metabolomics study — highlighting the fact that lactic
acid plays an important role in neuroinflammatory diseases such as TBM. Furthermore, this study reinforces our
belief that the determination of enantiomers of metabolites corresponding to infectious diseases is of critical
importance in substantiating the clinical significance of disease markers.
Keywords: Cerebrospinal fluid (CSF), Enantiomers, L- and D-lactic acid, Tuberculous meningitis (TBM),
Ultra-performance liquid chromatography–electrospray ionization–tandem mass spectrometry (UPLC–ESI–MS/MS)
Background
Lactic acid is a common metabolite and occurs as two,
optically active stereoisomers (enantiomers) — L-lactic
acid and D-lactic acid.
In humans, the L enantiomer is considered the normal,
physiological form of lactic acid. The endogenous D form
is also found in humans, but in nanomolar amounts due
to methylglyoxal metabolism [1], which converts acetone
derivatives to glutathione. The D enantiomer typically
originates from gut microbiota, such that it can be
detected in the blood and urine up to the millimolar
range. Elevation of D-lactic acid typically occurs as a result
of gut trauma or gastrointestinal disorder, for example, in
jejuno-ileal bypass for obesity [2], appendicitis [3, 4],
inflammatory bowel syndrome [5], and even in patients
with chronic fatigue syndrome [6] and type 2 diabetes [5].
The main source of elevated D-lactic acid in urine, how-
ever, is in patients with short bowel syndrome [7].
It is known that the gut possesses its own unique
microbiotic environment; it is also generally believed
that the brain is a fairly sterile environment without its
own microbiota, with the microglia in the circulating
cerebrospinal fluid (CSF) actively eliminating any
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microbial incursions beyond the blood–brain barrier
(BBB). However, in pathological conditions where an in-
vading pathogen successfully transgresses the BBB and
an infection occurs in the central nervous system (CNS),
any subsequent metabolic perturbations may be difficult
to trace and interpret. In the case of bacterial meningitis,
in which bacteria infect the meninges, with disastrous
consequences due to neuroinflammation, there have
been numerous reports of highly acidotic CSF owing to
the presence of lactic acid [8–10]. A unique form of bac-
terial meningitis, caused by Mycobacterium tuberculosis
(Mtb), is tuberculous meningitis (TBM). What makes
this form of meningitis unique, and dangerous, is that it
has a slow, insidious onset which often leads to accumu-
lated damage due to neuroinflammation, resulting in ir-
reparable neural damage, or even death. It is a disease
that is difficult to diagnose in its early stages and fatal if
recognized at a late stage. Of the various CSF diagnostic
markers for TBM, lactic acid is one that has been
reported in a limited number of studies [11–13]. In a
previous study we examined a cohort of infants and
children with TBM by means of an untargeted 1H nu-
clear magnetic resonance (NMR)-based metabolomics
approach [14]. The most noticeable feature that we de-
tected was highly elevated lactic acid (7.36 ± 2.36 mM)
in the CSF of these cases compared to the normal, age-
related reference range (1.65 ± 0.63 mM) [15]. The pres-
ence of highly elevated lactic acid in CSF is not unique
to meningitis cases: in patients with cerebral malaria
there was significantly higher CSF lactic acid recorded
(9.0 ± 5.3 mM [16]; 6.0 ± 1.0 mM [17]) in those who died
compared to survivors. Yao et al. [18] reported that CSF
lactic acid levels reflect the severity of metabolic impair-
ment of the brain in patients with hepatic encephalop-
athy. Thus, knowledge of increased CSF lactic acid levels
in response to neuropathology is not new; however,
distinguishing the respective roles of the L and D forms
has not been attempted hitherto.
In our NMR-based metabolomics study [14] the high
levels of lactic acid, together with several other statisti-
cally significant metabolites, led to the formulation of
the hypothesis: ‘The host’s response to neural infection
results in an “astrocyte–microglia lactic acid shuttle”
(AMLS) that operates in neuroinflammatory diseases,
such as TBM’; thereafter, a conceptual model describing
the AMLS was constructed. We are therefore seeing that
lactic acid, previously considered an unimportant by-
product of CNS metabolism, is now receiving more
attention as it appears to play an essential role in normal
neural homeostasis — in the astrocyte–neuron lactic
acid shuttle (ANLS) [19] — and possibly has an import-
ant role in neuropathological states. For example, lactic
acid is neuroprotective in cerebral ischemia [20], a
condition often associated with TBM.
In the present investigation, we used the CSF samples
collected in our previous study and employed a derivati-
zation method adapted from Scheijen et al. [5] to differ-
entiate the enantiomers of lactic acid present. We
analysed the samples using the highly sensitive, targeted
method of ultra-performance liquid chromatography–
electrospray ionization–tandem mass spectrometry
(UPLC–ESI–MS/MS). We report here for the first time
that highly lactic acidotic CSF from infants and children
with confirmed TBM exhibits only the L-enantiomer —
hence it is a response solely by the host to the infection
— and then discuss the relevance of the phenomenon of
elevated lactic acid in this example of a neuroinflamma-
tory disease.
Methods
Sampling
The experimental group consisted of infants and
children (<13 years of age) (n = 20) from the Western
Cape region of South Africa, who were directed from
local clinics to the paediatric unit of Tygerberg Hospital,
Cape Town, on suspicion of meningitis, based on clinical
symptoms. Upon admission to hospital, a lumbar CSF
sample was taken for differential diagnosis, a portion of
which was stored at −80 °C for this study, which was
used to confirm a diagnosis of TBM. A diagnosis of
TBM was based on the procedure of the uniform re-
search case definition of Marais et al. [21], practiced in
our clinical setting. Only children with ‘definite’ and
‘probable’ TBM were included in the present patient
group. TBM was classified as ‘definite’ when CSF dem-
onstrated acid-fast bacilli on microscopy, a positive Mtb
culture and/or passed a positive CSF Mtb commercial
nucleic acid amplification test in a child with symptoms
or signs suggestive of the disease. TBM was classified as
‘probable’ according to a scoring system based on clin-
ical, CSF and neuroimaging criteria, as well as evidence
of extraneural TB. Clinical details of the patients are
described in the Supplementary Information of Mason
et al. [14]. For the purpose of the present study the stage
of TBM, as well as the glucose concentration in 16 out
of the 20 CSF samples, were made available, as shown in
Fig. 2. We also collected a urine sample from our
subjects upon admission to hospital. Urine is often the
biofluid of choice for investigating the various potential
sources of lactic acid, as well as providing for a non-
invasive mode of sample collection. A limitation in using
urine remains the unpredictable fluctuation in the concen-
tration of targeted metabolites linked to the disease state
of the patients. Written consent was obtained from the
caregiver and assent if the child was older than 7 years
and competent to do so. This study was approved by the
Human Research Ethics Committee of Stellenbosch
University, South Africa (study no. N11/01/006) — informed
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consent and assent forms are given as additional information
in Additional file 1.
Chemicals
The chemicals used as standards were: sodium L-
lactic acid ≥99.0 % (Sigma-Aldrich 71718, CAS: 867-
56-1); sodium D-lactic acid ≥99.0 % (Sigma-Aldrich
71716, CAS: 920-49-0); sodium L-lactic acid-3,3,3-d3
(CDN isotopes D-2646, CAS: 79-33-4).
The following chemicals were used in sample prepar-
ation and analyses: (+)-O,O’-Diacetyl-L-tartaric anhyd-
ride (DATAN) (Sigma-Aldrich 358924, CAS: 6283-74-5);
acetonitrile HPLC supragrade (Biosolve 01203502, CAS:
75-05-8); MilliQ water (Millipore, CAS: 7732-18-5);
acetic acid 100 % (Merck 1.00063.1000, CAS: 64-19-7);
ammonium formate (Sigma-Aldrich 25204, CAS: 540-
69-2); dichloromethane (Lab-Scan AR1040A, CAS: 75-
09-2); perchloric acid (Sigma-Aldrich 244252, CAS:
7601-90-3); formic acid 98–100 % (Merck 1.00264.1000,
CAS: 64-18-6).
Sample preparation and UPLC-ESI-MS/MS analysis
A dilution series of L- and D-lactic acid and a
2.5 mM L-lactic acid-d3 internal standard (IS) solution
were prepared in advance for the calibration curve. A
fresh diacetyl-L-tartaric anhydride (DATAN) derivatiza-
tion solution was prepared by dissolving 250 mg of
DATAN in 4 mL dichloromethane and 1 mL acetic acid.
Samples were prepared by combining 50 μL CSF /
100 μL urine with 20 μL internal standard solution and
300 μL acetonitrile (ACN) in an Eppendorf tube. Sam-
ples were vortexed and centrifuged for 10 min at 3000
RPM in order to remove proteins and other macro-
molecules. The supernatant was transferred to a clean
glass vial and dried under nitrogen gas at 40 °C. To this,
100 μL DATAN solution was added, vortexed and
incubated at 75 °C for 30 min. Once again the solution
was dried under nitrogen gas at 40 °C and then reconsti-
tuted in 200 μL ACN / H2O (1/2 v / v) for UPLC-ESI-
MS/MS analysis. For the UPLC: eluent A (2.5 mM
ammonium formate, pH = 3.6) and eluent B (100 % aceto-
nitrile) were used. Samples were analysed on a Waters
Acquity UPLC hyphenated to a Quattro premier XE triple
quadrupole mass spectrometer using negative ion electro-
spray ionization — details given in Additional file 1.
After derivatization with DATAN, L- and D-lactic acid
were separated from each other on the UPLC column
and measured by MS/MS in MRM mode. Use of solvent
delay time avoided the introduction of salts in the MS.
Results were quantified in terms of the stable isotope-
labelled analogue of L-lactic acid. The peak areas
corresponding to component-specific transitions were
converted via calibration lines to concentrations.
Results
Using a spiked sample containing both the L and D
forms of lactic acid, and comparing the chromatogram
qualitatively with the stable isotope (L-lactic acid-d3), it
was evident that the UPLC–ESI–MS/MS method used
in this study was able to differentiate between the two
enantiomers (Fig. 1a and b). We were therefore able to
identify and quantify the lactic acid content of the CSF
samples from the 20 TBM cases, as described in the
‘Methods’ section. These results revealed that the lactic
acid was exclusively in the L-form — no D-isomer was
detected (Fig. 1c) — with a mean concentration of
5.2 mM (SD = 2.6; range: 1.5–10.5 mM).
We also compared the total lactic acid concentrations
in the corresponding samples with those derived from
the UPLC–ESI–MS/MS method used in the current
study and with those from the NMR method of Mason
et al. [14], and found a strong linear relationship be-
tween the two sets of results (r = 0.93), with a statistically
significant positive correlation (0.86) and a statistically
strong validation of the fit with an R2 value of 0.73.
These data therefore confirm that both methods are
highly comparable, demonstrating high reproducibility.
Of the 20 CSF samples examined, a clinician reported
glucose values for 16 samples. Figure 2 is a scatterplot,
showing both the lactic acid and glucose concentrations of
the CSF, with the corresponding stage of the TBM disease.
This figure illustrates the inverse relationship between lactic
acid and glucose, together with the patient severity out-
come after treatment. Additional statistics (shown in Add-
itional file 1) support existing knowledge that glucose is
significantly correlated with TBM stage and outcome sever-
ity. While L-lactic acid reached high concentrations in CSF
samples in some patients from the present group (well
above the reference ranges), the L-lactic acid did not
correlate with statistical significance with the TBM stage or
outcome severity — an observation that may, however,
relate to the small sample size of the present group.
In addition to the CSF, the urine was examined of 7 pa-
tients upon admission to hospital. Both the L and D forms
of lactic acid were detectable (illustrated in Fig. 1d), but in
small amounts. The mean urine lactic acid was determined
to be 98.4 μM for the L form (SD = 37.4; range: <50–
155 μM) and 47.4 μM for the D form (SD = 56.7; range:
nd–148 μM). The contribution of D-lactic acid from the
gut microbiota cannot be distinguished from any possible
influence of the Mtb, and the small amount of urinary lactic
acid was well within the normal range. We conclude that
urine is not a suitable biofluid for monitoring and assessing
lactic acid for diagnostic purposes in TBM.
Discussion
In the present investigation we identified and quantified
the L and D enantiomers of lactic acid in the CSF of 20
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cases of infants and children with confirmed TBM, using
UPLC–ESI–MS/MS. This study was motivated by our
NMR-based metabolomics study [14], in which the most
prominent feature of the CSF of these TBM cases was
highly elevated lactic acid. We therefore sought to deter-
mine the source and form of the lactic acid — was it a re-
sponse from the host (which would generate the L-isomer),
of microbial origin (which produces the D-isomer), or
both? Because NMR is incapable of distinguishing the
enantiomers of lactic acid, we conducted this follow-up
study with the means to identify the separate isomers.
We have shown that both enantiomers were detectable
in urine samples, but the elevated lactic acid in the CSF
samples of the TBM patients consisted of only L-lactic
acid, and hence was produced exclusively by the host
with no contribution from the Mtb. Moreover, Fig. 2
shows that as the TBM disease progressed into later
stages there was a drop in patient prognosis (i.e., in-
creased outcome severity). Generally, in more advanced
TBM stages, fewer energy substrates are available for
microglia activity and decreased protection of neurons
from the lactic acid. During this period, irreversible
Fig. 1 Representative chromatograms depicting a definitive identification of L-lactic acid using the stable isotope (L-lactic acid-d3); b clear differentiation of
L and D forms of lactic acid in the spiked sample; c in CSF, complete lack of D form of lactic acid with only the L form present; and d presence of both L
and D forms of lactic acid in urine
Fig. 2 Scatterplot showing the concentration of lactic acid in the CSF samples and the corresponding CSF glucose (values not reported in text)
over different stages of TBM disease (dashed lines indicate respective reference ranges). Outcome severity: green circle= normal; yellow circle =mild
neurological problems (e.g., learning difficulties, visual impairment); black circle = severe neurological problems (e.g., partial paralysis, severe motor
impairment, cranial nerve palsy). *TBM stage: 1 = Glasgow coma score (GCS) 15 and no focal neurology; 2a = GCS 15 plus focal neurology; 2b = GCS
11–14 with focal neurology; 3 = GCS <11
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neurological damage can begin to occur. Lactic acid
boosts energy production in the brain and increases
neuroprotection, thus potentially improving the prog-
nosis of patients, especially those at high risk. TBM
patients in late stages of the disease who exhibit CSF
with low lactic acid and glucose may be beyond help
as the accumulated neural damage and lack of energy
substrate can be fatal.
The origin and rationale of high levels of lactic acid
produced by the host in response to a neuroinflamma-
tory disease such as TBM is unclear. Interconversion of
lactic acid and pyruvate occurs via lactate dehydrogen-
ase, with increased lactic acid typically being associated
with anaerobic respiration. Thus, elevated levels of lactic
acid in the CSF due to neuroinflammation could be due
to hypoxia caused by ischemia, or by increased glucose
levels and hence increased flow through the glycolysis
pathway. However, in TBM cases there are typically low
levels of glucose in the CSF [22], corresponding to a
CSF to serum glucose ratio less than 0.5 or an absolute
CSF glucose concentration of less than 2.2 mM. Further-
more, several studies have shown no correlation between
CSF lactic acid levels and cerebral blood flow (i.e., they
are unrelated to ischemia) [23–25]. Thus, elevated lactic
acid in CSF of TBM cases is unlikely to be due to anaer-
obic respiration but instead is possibly a product of
temporarily increased flux in the glycolysis pathway.
The results reported here also provide experimental
evidence which supports our proposed AMLS hypoth-
esis [14]. The hypothesis postulates that, when the brain
is in crisis due to neuroinflammatory-inducing infection,
energy flow in brain metabolism is shifted away from the
neurons and shunted towards the microglia. Hence, in
neuroinflammatory infectious diseases, such as TBM,
lactic acid produced by glycolysis in astrocytes partici-
pates in the activated immune response and, in associ-
ation with ketones and gluconeogenic amino acids, is
collectively directed from the neurons preferentially into
microglia where it enters the mitochondrial citric acid
cycle. This process contributes to oxidative phosphoryl-
ation and hence produces high levels of adenosine tri-
phosphate (ATP) and forms of reactive oxygen species,
such as hydrogen peroxide, required for degradation of
the invading pathogen.
Further studies are needed to advance our understand-
ing of the dynamics involved in this lactic acid
phenomenon — for example: determining the rate at
which microglia produce lactic acid under neuroinflam-
matory conditions such as TBM; an in vitro scenario
testing whether a high level of lactic acid within the
microglia reduces the uptake of interstitial lactic acid
due to concentration gradients, accounting for the high
concentrations of lactic acid in the CSF; more in-depth
studies into transporters that shuttle lactate, namely,
monocarboxylate transporters; and, in a clinical setting,
determining the impact of adjunctive treatments involv-
ing direct infusion of sodium lactate into the CSF of
advanced stage TBM patients.
While simple in design and execution, this study pro-
vides important information not reported before. The
implications of these results are compelling in that the
levels of lactic acid in the CSF, produced by the host,
should be carefully considered by the clinician, especially
regarding neuroinflammatory diseases. The reason for
this is that lactic acid is used preferentially over glucose
in such cases [26–30], provides a boost in neuroprotec-
tion [31, 32], and aids microglia energy demands in their
bactericidal actions. Thus lactic acid has a potential
beneficial role in the clinical management of neuro-
logical disorders [33].
Conclusions
In summary, we have shown that the contribution from
Mtb in the form of D-lactic acid in all our TBM-infected
CSF cases was not demonstrable. The lactic acid con-
sisted solely of the L-form, with the host being respon-
sible for its high concentrations in the CSF. Beyond this
study, the ramifications of determining the enantiomers —
and by doing so the origin — of particular metabolites
holds importance for future research. Knowledge of what is
produced by the host and what is of microbial origin could
revolutionize treatment regimes and allow us to understand
disease pathogenesis and progress better. Therefore adapta-
tion of the method presented should be made routine for
common, optically active markers of disease to determine
their respective enantiomers, particularly in the field of
metabolomics.
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